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A number of peripheral blood analytes have been proposed as potential biomarkers of
post-traumatic stress disorder (PTSD). Few studies have investigated whether observed
changes in biomarkers persist over time. The aim of this study was to investigate the
association of combat-related chronic PTSD with a wide array of putative PTSD biomark-
ers and to determine reliability of the measurements, i.e., correlations over time. Croatian
combat veterans with chronic PTSD (n=69) and age-matched healthy controls (n=32),
all men, were assessed at two time points separated by 3 months. Serum levels of lipids,
cortisol, dehydroepiandrosterone-sulfate (DHEA-S), prolactin, and C-reactive protein were
determined. Multiplex assay was used for the simultaneous assessment of 13 analytes
in sera: cytokines [interferon-γ, interleukin (IL)-1β, IL-2, IL-4, IL-6, TNF-α], adhesion mole-
cules (sPECAM-1, sICAM-1), chemokines (IL-8 and MIP-1α), sCD40L, nerve growth factor,
and leptin. Group differences and changes over time were tested by parametric or non-
parametric tests, including repeated measures analysis of covariance. Reliability estimates
[intraclass correlation coefficient (ICC) and kappa] were also calculated. Robust associa-
tions of PTSD with higher levels of DHEA-S [F (1,75)=8.14, p=0.006)] and lower levels
of prolactin [F (1,75)= 5.40, p=0.023] were found. Measurements showed good to excel-
lent reproducibility (DHEA-S, ICC=0.50; prolactin, ICC=0.79). Serum lipids did not differ
between groups but significant increase of LDL-C after 3 months was observed in the
PTSD group (t =6.87, p<0.001). IL-8 was lower in the PTSD group (t =4.37, p<0.001)
but assessments showed poor reproducibility (ICC=−0.08). Stable DHEA-S and prolactin
changes highlight their potential to be reliable markers of PTSD. Change in lipid profiles after
3 months suggests that PTSD patients may be more prone to hyperlipidemia. High intra-
individual variability in some variables emphasizes the importance of longitudinal studies
in investigations of PTSD biomarkers.
Keywords: post-traumatic stress disorder, veterans, biological markers, cholesterol, cytokines, cell adhesion
molecules, nerve growth factor, leptin
INTRODUCTION
Long-term mental and physical health consequences of trauma
place a significant burden on healthcare systems, especially in areas
with a recent history of conflict where the majority of the popula-
tion has been affected by war (1, 2). Post-traumatic stress disorder
(PTSD) has been found to be the most frequent mental disor-
der 5–15 years after the war in the Balkans (3). Moreover, PTSD
has been associated with various somatic comorbidities with par-
ticularly strong evidence for higher prevalence of cardiovascular
(4–6) and autoimmune (7–9) diseases. Various metabolic, hor-
monal, and immune-related changes that could lead to somatic
diseases have been observed in PTSD. In the majority of stud-
ies to date, PTSD patients exhibited unfavorable lipid profiles,
either alone (10–15) or as a part of metabolic syndrome (16, 17),
which reflects increased cardiovascular disease (CVD) risk. There
is also substantial evidence for dysregulation of the hypothalamic–
pituitary–adrenal (HPA) axis with decreased levels of blood and
urinary cortisol and enhanced sensitivity of the HPA axis to nega-
tive feedback (18). These alterations could influence lipid metab-
olism (19) and contribute to immune system activation leading
to peripheral inflammation reflected by elevated circulating levels
of cytokines and acute phase reactant C-reactive protein (CRP)
(20). Given the complex neuroendocrine–immune interactions
observed in PTSD, researchers have utilized assays that allow for
simultaneous detection of multiple analytes in a limited amount
of sample and found a broad spectrum of increased circulating
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peripheral levels of pro-inflammatory cytokines and chemokines
(21, 22). Prolactin, as an immunostimulatory hormone (23), may
be partly involved in the processes leading to immune activation in
PTSD (24). Neurosteroid dehydroepiandrosterone (DHEA) and
its sulfated ester form dehydroepiandrosterone-sulfate (DHEA-
S) are other components of the HPA axis that may be altered
in PTSD (25) and contribute to immune activation through
their immunostimulatory and anti-glucocorticoid effects (26). A
substantial number of reports showed elevated DHEA and/or
DHEA-S concentrations in PTSD patients (27–33).
However, results from many studies are not consistent with
the above mentioned findings in PTSD. For example, studies have
reported serum lipids as unchanged (34, 35), and no change or
elevation in basal cortisol levels (18, 36, 37). Prolactin levels were
found to be decreased or unchanged (38–41), as well as DHEA(-S)
levels (42–44) in addition to reports of no change in basal cir-
culating levels of multiple cytokines (45). As for other potential
biomarkers of PTSD, the reasons for these inconsistencies are com-
plex and multifactorial (46) and as a result, no valid and reliable
single PTSD biomarker has been identified to date (47).
While there are a growing number of prospective studies inves-
tigating PTSD risk/resilience markers (48, 49), studies of disease
markers have typically been cross-sectional. Biological markers
show substantial variability with great overlap between PTSD and
non-PTSD groups, so large sample sizes are needed to obtain
enough statistical power to confirm differences. Measurements
are seldom repeated during the course of the disease to assess how
stable the observed changes are over time.
The aim of this study was to investigate the association of
combat-related chronic PTSD with the serum levels of lipids,
stress-related hormones (cortisol, DHEA-S, prolactin), CRP,
cytokines and other immune-related soluble molecules, nerve
growth factor (NGF), and leptin. The second aim was to deter-
mine whether the observed changes remained consistent after
3 months during the course of disease and measurement reliabil-
ity. We hypothesized that biological changes associated with PTSD,
i.e., possible PTSD biomarkers, would be inert to repetitive testing
during the course of chronic PTSD.
MATERIAL AND METHODS
SUBJECTS
Ninety-eight PTSD patients were recruited among outpatients at
the “Dr. Josip Bencˇevic´” General Hospital, Slavonski Brod, Croa-
tia. The patients were male combat veterans who were severely
traumatized during the war in Croatia (1991–1995) and have
undergone several forms of psychiatric treatment since the war
ended. Before inclusion in the study, patients have been continu-
ously treated in an outpatient program for at least 10 years. They
were at least once treated in a day hospital program and/or inpa-
tient program. The treatment included supportive psychotherapy
and/or cognitive-behavioral therapy as well as various sociother-
apeutic interventions. During this period, every patient received
multiple medication trials. Considering all this, the patients could
be regarded as treatment-resistant (50). During the recruitment,
all patients met the ICD-10 (51) PTSD criteria (the official classifi-
cation in Croatian psychiatric practice) and they were treated in an
outpatient program, which included regular appointments with
psychiatrist and medications. Due to the ethical considerations,
medication washout could not be performed. The medications
prescribed were recorded based on patients’ last visit to psychia-
trist before assessments. The type of medication did not change
during the study period. Patients were asked to participate in the
study during the regular appointment in the hospital or by tele-
phone call. The study procedures were fully explained to them
and they were instructed to restrict from food intake at least
12 h before the blood draw, which was scheduled at 7–9 a.m.
on the day of the assessments. They were also asked to inform
their friends and relatives who were not treated for PTSD about
possible participation in the study. We were able to recruit 33
control subjects among patients’ and researchers’ acquaintances
and hospital workers. They were age-matched men who had been
civilian residents of the same (war-affected) area during the war
and were never treated for PTSD. The Ethic Committee of the
hospital approved the study and written informed consent was
obtained from all subjects on the day of the first assessment.
A subset of blood samples randomly selected from participants
in this study was used to examine the phenotype of regula-
tory T cells in PTSD patients and this data have recently been
published (52).
The first assessment (time 1) was performed on November
11 2009. At the day of the assessment, all study participants
were examined by an experienced psychiatrist and medical his-
tory data relevant to the purpose of this study were recorded.
After measuring blood pressure and collecting the blood sam-
ple, the subjects were asked to complete rating scales for PTSD,
depression, and anxiety symptoms. The diagnosis was confirmed
if a participant fulfilled criteria for PTSD by rating 17 diagnostic
items of the 43-item version of the Los Angeles Symptom Check-
list (LASC) (53). This instrument proved to be highly a reliable
self-report symptom checklist that includes the DSM-III-R (54)
criteria for PTSD as a subset [coefficient alpha of 0.94 for the 17
items specifically assessing PTSD symptoms (55)] and it was used
to quantify re-experiencing, avoidance, and arousal symptoms of
PTSD. Respondents rated the extent to which specific symptoms
were a problem for them, using a 5-point Likert-type scale ranging
from 0 (no problem) to 4 (extreme problem). For a diagnosis of
PTSD, the respondent must rate (with a rating of two or higher)
at least one item assessing re-experiencing (represented by three
items), three items (out of six items) related to avoidance and
numbing, and two items reflecting increased arousal (represented
by eight items). If a respondent endorses two of the three criteria,
a partial PTSD diagnosis may be considered. Depression symp-
toms were assessed with the Beck Depression Inventory (BDI) (56)
and anxiety level (state and trait) was determined by the Spiel-
berger State-Trait Anxiety Inventory (STAI) (57). Demographic
data, smoking, and alcohol use were assessed by a custom question-
naire. Current smokers were participants who reported smoking
cigarettes every day (daily) or some days (non-daily). Participants
who were former smokers or never smoked a cigarette were con-
sidered non-smokers. Frequency of alcohol use during the past
12 months was determined on the basis of following response cat-
egories (separately for wine/beer and spirits): (1) every day, (2)
3–5 times/week, (3) once a week, (4) less than once a month, (5)
never. Since all participants who drank responded with categories
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2 and 3, we decided to merge these categories and report alcohol
consumption as “at least one drink per week.”
Healthy controls did neither report experiences that would clas-
sify as criterion A (traumatic event) for PTSD diagnosis nor did
they meet lifetime or current criteria for any psychiatric disor-
der and had no symptoms or signs of current psychiatric disease.
Exclusion criteria for both groups were substance abuse, symptoms
or signs of acute or chronic physical illnesses, including infectious,
allergic, or endocrine disorders, and the use of glucocorticoids.
Five patients were excluded because they did not fulfill criteria
for PTSD diagnosis. They reported traumatic event(s) (as opposed
to controls) but did not satisfy a single PTSD criterion according to
LASC 17-item PTSD index. Fifteen patients were excluded because
of chronic illnesses: asthma (n= 1), diabetes (n= 3), multiple
sclerosis (n= 2), chronic pancreatitis (n= 1), Parkinson disease
(n= 1), psoriasis (n= 2), ulcerative colitis (n= 1), and cancer
(n= 4). Another eight patients and one control were excluded
because they reported at least one general symptom of current
somatic disease (e.g., fever or fatigue) and had CRP>10 mg/L indi-
cating acute inflammation or infection. They were asked to repeat
blood tests after a week and CRP levels went down to normal. One
patient was excluded because of age (>65 years). This yielded a
total of 29 patients and 1 control subject who were excluded from
the study.
The second assessment (time 2) was performed on February
8, 2010 and all procedures performed at the first assessment were
repeated by the same group of professionals to minimize sources
of variability. Six PTSD patients and five control subjects did not
show up at the follow-up.
BLOOD SAMPLING AND ASSAYS
Blood samples were taken by venipuncture from all participants on
the same day between 7 and 9 a.m. at both assessments. Blood was
collected into 10-mL Vacutainer tubes (Becton Dickinson Vacu-
tainer System Europe, Grenoble, France) without anticoagulant.
One serum tube was sent to the hospital laboratory for immediate
determination of serum lipids and CRP levels. Triglycerides, total
cholesterol, high-density lipoprotein cholesterol (HDL-C), and
low-density lipoprotein cholesterol (LDL-C) were determined on
a Beckman Coulter AU680 analyzer (Beckman Coulter, Mishima,
Japan) (58). Determination of CRP was performed using a stan-
dard latex immunoassay; CRP Vario (Abbott Diagnostics, Lake
Forest, CA, USA). Another serum tube was transported to the
research laboratory for determination of cortisol, DHEA-S, and
prolactin concentrations, as well as concentrations of analytes that
were measured by multiplex immunoassay (henceforth termed
“multiplex analytes”). Separation of sera in the research laboratory
was performed within 2 h of the blood draw. After separation, the
sera were stored at−80°C until assayed.
Serum concentrations of cortisol, DHEA-S, and prolactin were
determined by enzyme-linked immunosorbent assay (ELISA)
kits from the same manufacturer in both assessments (NovaTec
Immunodiagnostica GmbH, Dietzenbach, Germany) according
to the manufacturer’s instructions. The sensitivity of the cortisol
assay was 5 ng/mL, and the intra-assay and inter-assay coefficients
of variation (CV) were 7 and 9%, respectively. DHEA-S assay had
the sensitivity of 0.045µg/mL with the intra-assay CV of 4.8% and
the inter-assay CV of 8.9%. The sensitivity of the prolactin assay
was 1 ng/mL with the intra-assay and inter-assay CVs of 1.4–3.5
and 3.5–5.4%, respectively.
Simultaneous determination of 13 analytes per one serum sam-
ple was performed by bead-based multiplex immunoassay for the
flow cytometer (FlowCytomix™ Multiple Analyte Detection Sys-
tem, Bender MedSystems GmbH, Vienna, Austria). The assay was
customized to include following analytes: cytokines [interferon
(IFN)-γ, interleukin (IL)-1β, IL-2, IL-4, IL-6, TNF (tumor necro-
sis factor)-α], soluble (s) adhesion molecules [sPECAM (platelet
endothelial cell adhesion molecule)-1, sICAM (intercellular adhe-
sion molecule)-1], chemokines [macrophage inflammatory pro-
tein (MIP)-1α and IL-8], sCD40 ligand (L), NGF, and leptin. Assay
sensitivities for each analyte are included in Table 3. Intra- and
inter-assay CVs were all below 10% except IL-4, with the docu-
mented intra-assay CV of 15% and inter-assay CV being 16.3%.
Samples were analyzed with LSR II flow cytometer (BD Bio-
sciences, Mountain View, USA) and official manufacturer’s soft-
ware (FlowCytomix™ Pro Software, Bender MedSystems GmbH,
Vienna, Austria) was used to calculate analyte concentrations.
STATISTICAL ANALYSES
Distribution normality for all continuous variables was assessed
within each group by visual inspection of the data (shape and
symmetry of distribution) and by Shapiro–Wilk’s W -test.
Participants’ characteristics were compared with independent
sample t -tests, Fisher’s exact tests for 2× 2 contingency tables, and
Pearson’s chi-square tests for larger contingency tables.
Data for serum lipids, hormones measured by ELISAs, and
CRP were available for both groups at both assessments. Since
there were 11 dropouts (6 in the PTSD group and 5 in the control
group), missing data analysis was performed to test if data were
missing at random. Available data at the first assessment were
compared between missing and non-missing groups using non-
parametric tests (Fisher’s exact test or Pearson’s chi-square test
for categorical variables and Mann–Whitney’s test for continuous
variables). Another test of randomness was a logistic regression
predicting missingness at the second assessment (0= not missing,
1=missing) from all other variables at the first assessment. Since
all the tests confirmed that there was no difference between miss-
ing and non-missing groups, we concluded that data were missing
completely at random (MCAR). Therefore, we assumed that esti-
mates would not be biased if we analyzed only available cases. Due
to technical reasons, some values at the second assessment were
still missing in the PTSD group (two missing values for cholesterol,
triglycerides, HDL, CRP, and five missing values of LDL) and in
the control group (one missing value for cholesterol, triglycerides,
HDL, LDL, and CRP distributed among different cases). These
values were imputed with the corresponding value from the data
obtained at the first assessment (last observation carried forward
method). Variables that were not normally distributed (triglyc-
erides, DHEA-S, prolactin, CRP) were log-transformed. Repeated
measures analysis of covariance (RM ANCOVA) was performed
to test the effect of time (within-subjects, two levels) and group
(between-subjects, two levels). If the interaction effect was signif-
icant, post hoc t -tests for dependent or independent samples were
performed. Possible confounding factors (included in the model
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as covariates) were chosen based on previous studies and their
expected influence of medication on biological variables. These
factors included age, smoking (current smoker vs. non-smoker),
alcohol use (at least one drink per week vs. never), and medication
use (10 binary variables related to prescribed drug type). All vari-
ables followed multivariate normal distribution as tested by Box’s
test of equality of covariance matrices.
A multiplex assay was performed in all subjects at the first
assessment, but due to the lack of resources, analysis was repeated
in randomly selected 47 PTSD patients. Using the same approach
as described above, missing data analysis confirmed that there
was no difference between selected PTSD patients and other
patients in variables assessed at the first assessment. Samples with
values below the lower limit of detection (LOD) were replaced
with a zero for the purpose of continuous data analyses. Seven
out of 13 multiplex analytes (sCD40L, sPECAM-1, sICAM-1,
Leptin, MIP-1α, IL-8, IL-1β) had concentrations below LOD in
<30% of samples and they were analyzed as continuous vari-
ables. Other variables (IL-2, TNF-α, IFN-γ, NGF, IL-4, IL-6) were
dichotomized (detectable vs. non-detectable) and analyzed as cat-
egorical variables. Continuous variables were log-transformed to
obtain normal distribution and were compared with t -tests for
independent and dependent samples. Since IL-1β did not fol-
low a Gaussian distribution even after every commonly used
transformation, non-parametric Mann–Whitney’s and Wilcoxon
signed-rank tests were used. Categorical variables were compared
using Fisher’s exact tests or McNemar’s tests for paired data. To
minimize the possibility of type I error because of the mul-
tiple comparisons performed, we used the false discovery rate
method (FDR) (59). FDR threshold value (d) was calculated with
significance level (α) set to 0.05 for 26 comparisons related to
multiplex analytes. One-way ANCOVA was used to check the
influence of confounding factors in variables that were signifi-
cantly different between groups. To test for associations between
confounding factors and other variables, subgroup analyses with
non-parametric (Mann–Whitney’s U or Fischer’s exact) tests were
performed.
The intraclass correlation coefficient (ICC) was calculated for
continuous variables to test the reliability (i.e., the ability to
differentiate between subjects or group of subjects) of labora-
tory methods and psychometric tests. To calculate ICC, we used
one-way random-effects ANOVA model and the following for-
mula: σ2B/(σ
2
W + σ2B); between-subject variance/(within-subject
variance+ between-subject variance). Although repeated mea-
surements were performed by the same methods and the same
raters, they were separated by a relatively long period of time.
Therefore, we assumed that measurements were made under
changing conditions, which means that the ICC was an esti-
mate of reproducibility (60). According to Fleiss (61), an ICC
≥0.75 indicates excellent reproducibility, 0.4≤ ICC< 0.75 indi-
cates fair to good reproducibility, and ICC <0.4 indicates poor
reproducibility. Additionally, kappa coefficients were calculated to
evaluate agreement between measurements of the multiplex ana-
lytes that were represented as binary variables. As suggested by
Altman (62), κ< 0.20 represents poor agreement, 0.21–0.40 fair,
0.41–0.60 moderate, 0.61–0.80 good, and 0.81–1.00 a very good
agreement.
Correlations between the psychometric test scores and bio-
logical variables were performed with Spearman’s rank order
correlations. A total of 168 correlations (21 biological× 8 psycho-
metric variables) were performed in each time point and between
time points. The FDR method was used to account for multiple
correlations.
Statistical analyses were performed with Statistica v8 (StatSoft
Inc., Tulsa, OK, USA).
RESULTS
PARTICIPANTS’ CHARACTERISTICS AND PSYCHOMETRIC TEST SCORES
As seen in Table 1, groups were matched in age and marital
status. PTSD patients were less educated with a higher pro-
portion of control subjects having university education. The
majority of PTSD patients were retired, as opposed to con-
trols. There were more current smokers in the PTSD group but
a higher proportion of control subjects reported alcohol con-
sumption (at least one drink per week). Blood pressure did not
differ between groups and did not change over 3 months. As
expected, PTSD patients had higher scores in all psychomet-
ric tests at the first assessment (Table 1). Although the level of
PTSD symptoms that patients reported declined [re-experiencing,
5.4± 2.6 (score± SD), t = 9.25, p< 0.001 (compared to the first
assessment); avoidance, 9.0± 5.3, t = 7.23, p< 0.001; arousal,
13.1± 6.3, t = 11.14, p< 0.001; 17-item PTSD index, 27.5± 13.2,
t = 10.9, p< 0.001; 43-item index, 55.0± 28.1, p< 0.001], they
were still higher when compared to control subjects at the second
assessment [re-experiencing, 1.1± 1.6, t = 9.49, p< 0.001; avoid-
ance, 3.26± 3.9, t = 5.73, p< 0.001; arousal, 4.9± 5.7, t = 6.11,
p< 0.001; 17-item PTSD index, 9.2± 10.4, t = 6.87, p< 0.001;
43-item index, 21.4± 21.9, t = 6.09, p< 0.001]. Fourteen out of
69 patients (20%) did not meet diagnostic criteria for PTSD. Since
those patients endorsed two of the three LASC criteria, their con-
dition could be regarded as partial PTSD. Similarly, BDI scores also
declined in PTSD patients (12.3± 10.2, t = 12.08, p< 0.001) but
remained elevated in comparison to controls at the second assess-
ment (4.7± 6.3, t = 4.13, p< 0.001). The same pattern was also
observed for STAI scores (data not shown). The majority of PTSD
patients (n= 57, 83%) were treated with psychotropic medication:
antidepressants (n= 47, 68%), anxiolytics (n= 49, 71%), hyp-
notics (n= 46, 67%), antipsychotics (n= 16, 23%), and mood sta-
bilizers (n= 3, 4%). Other drugs that PTSD patients used included
non-steroidal anti-inflammatory drugs (n= 12, 17%), opioid
analgesics (n= 2, 3%), hypolipidemics (n= 7, 10%), antihyper-
tensives (n= 12, 17%), and proton pump inhibitors (n= 6, 9%).
SERUM LIPIDS, HORMONES, AND CRP
Results of RM ANCOVA analyses controlling for age, smoking,
alcohol use, and medication use (10 variables) are shown in
Table 2.
No significant main effects were recorded for serum lipids.
However, since the interaction effect was significant for LDL-C,
post hoc analyses showed significant elevation of LDL-C con-
centrations only in PTSD patients (t = 6.87, p< 0.001) and not
in control subjects (t = 0.59, p= 0.559), although there were no
group differences in individual time points. This tendency was also
observed for triglycerides and total cholesterol as seen from raw
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Table 1 | Participants’ characteristics and psychometric test scores
(first assessment).
PTSD
(n=69),
mean±SD
or n(%)
Controls
(n=32),
mean±SD,
or n (%)
Statistical
value
p-value
Age (years) 47.12±5.92 45.56±7.24 1.14a 0.256
Education
Elementary school 12 (17.4) 0 (0) 9.53b 0.009
High School 52 (75.4) 25 (78.1)
University 5 (7.2) 7 (21.9)
Work status
Unemployed 5 (7.2) 1 (3.1) 76.30b <0.001
Retired 60 (87.0) 1 (3.1)
Employed 4 (5.8) 30 (93.8)
Marital status
Single/divorced 14 (20.3) 2 (6.2) Exact testc 0.072
Married 55 (79.7) 30 (93.8)
Current smoker 37 (53.6) 5 (15.6) Exact testc <0.001
Alcohol use 14 (20.3) 14 (43.8) Exact testc 0.014
Systolic blood
pressure (mmHg)
131.5±17.1 132.6±23.1 0.30a 0.766
Dyastolic blood
pressure (mmHg)
84.3±12.0 85.6±14.7 0.49a 0.625
LASC scores
Re-experiencing 8.4±1.8 1.4±1.9 17.54a <0.001
Avoidance 15.0±3.6 4.3±4.3 12.95a <0.001
Arousal 22.6±5.0 5.0±5.2 17.24a <0.001
17-item PTSD
index
46.1±8.8 10.7±10.7 17.51a <0.001
43-item full scale
index
95.0±21.3 24.4±23.6 14.94a <0.001
BDI score 31.1±9.0 5.3±5.8 14.77a <0.001
STAI-State score 58.4±11.3 37.7±9.9 9.21a <0.001
STAI-Trait score 58.8±6.9 37.5±11.6 12.29a <0.001
BDI, Beck Depression Inventory; LASC, Los Angeles Symptom Checklist; PTSD,
post-traumatic stress disorder; SD, standard deviation; STAI, Spielberger State-
Trait Anxiety Inventory.
at-value: independent sample t-tests.
bχ2-value: Pearson’s chi-square tests for larger contingency tables.
cExact test: Fisher’s exact tests for 2× 2 contingency table.
values in Table 2. Tests of between-subject effects showed signifi-
cant effect of smoking in RM ANCOVA model [F(1,75)= 11.07,
p< 0.001] with triglycerides levels being significantly higher in
smokers at the second assessment (t = 3.31, p= 0.001). Signif-
icant between-subjects effects in the model for total choles-
terol were found for antipsychotics [F(1,75)= 5.57, p= 0.021]
and hypolipidemics [F(1,75)= 4.62, p= 0.035]. Total cholesterol
levels were higher in those using antipsychotics (n= 15) at the first
assessment (t = 2.48, p= 0.022) and tended to be higher at the
second assessment (t = 2.02, p= 0.057). As expected, total choles-
terol levels were lower in patients using hypolipidemics (n= 7) at
the first (t = 4.53, p= 0.001), as well as at the second assessment
(t = 6.13, p< 0.001). No such effects were observed for LDL-C or
HDL-C.
A significant effect of group was revealed for DHEA-S and pro-
lactin, meaning that concentrations of these two hormones were
altered in PTSD patients at both time points even after adjusting
for confounding factors. DHEA-S levels were higher while pro-
lactin levels were lower in PTSD patients. As shown by a significant
effect of time, DHEA-S and cortisol levels declined in both groups.
C-reactive protein levels tended to be higher in PTSD patients at
both time points. However, no significant effect in RM ANCOVA
model was found. A significant interaction of time and smok-
ing in tests of within-subjects effects [F(1,75)= 4.01, p= 0.049]
indicated that smoking was an important confounding factor.
Indeed, when RM ANOVA was performed without covariates, the
effect of group was significant [F(1,75)= 5.33, p= 0.023]. Addi-
tion of smoking as covariate blunted the effect [F(1,75)= 3.04,
p= 0.085]. Moreover, t -tests revealed higher CRP concentration
in smokers (n= 38) compared to non-smokers (n= 52) (t = 2.28,
p= 0.025).
MULTIPLEX ANALYTES
The comparison of multiplex assay analytes between PTSD
patients and controls at the first assessment is shown in Table 3.
A significant difference was observed only for IL-8 with its con-
centration being lower in PTSD patients. When only drug-free
patients (n= 12) were compared to control subjects (n= 32), IL-8
was still significantly lower in PTSD patients (Z = 2.54, p= 0.011)
with no change in other variables. However, in one-way ANCOVA
model with IL-8 as a dependent variable and age, smoking, alcohol
use, and medication use (10 variables) as covariates, the effect of
group was not significant [F(1,89)= 3.41, p= 0.069]. Concentra-
tions of sCD40L and sPECAM-1 significantly declined in PTSD
patients while levels of IL-8 and IL-1β were higher in comparison
to levels at the first assessment (Table 4). A higher percentage of
samples were detectable for IL-2 and IL-6 at the second assessment.
Subgroup analyses revealed higher concentrations of sICAM-
1 (Mann–Whitney Z = 3.26, p= 0.001) and leptin (Z = 2.84,
p= 0.005) in patients taking hypolipidemics at the first assess-
ment. At the second assessment, patients who were using
hypolipidemics had higher concentrations of MIP-1α (Z = 2.83,
p= 0.005). A lower concentration of sICAM-1 was observed in
patients who were taking antipsychotics (Z = 2.87, p= 0.004) at
the first assessment. No influence of smoking was revealed in
subgroup analyses.
REPRODUCIBILITY AND AGREEMENT BETWEEN MEASUREMENTS
As seen in Table 5, fair to good reproducibility was observed
for determination of all serum lipids, DHEA-S, CRP, sCD40L,
and sICAM-1. Repeated measurements of prolactin, sPECAM,
leptin, MIP-1α, and IL-1β showed excellent reproducibility. Deter-
mination of cortisol and IL-8 was associated with poor repro-
ducibility meaning that within-subject variance was greater
than between-subject variance. LASC 17-item PTSD index and
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Table 2 | Serum lipids, hormones, and C-reactive protein (CRP) analyzed by repeated measures analysis of covariance (RM ANCOVA).
Variablea Time 1, mean±SD or
median (Q1–Q3)
Time 2, mean±SD or
median (Q1–Q3)
RM ANCOVA effects
(df =1,75)b
PTSD
(n=63)
Controls
(n=27)
PTSD
(n=63)
Controls
(n=27)
Group,
F (p)
Time,
F (p)
Interaction,
F (p)
Serum lipids
Triglycerides (mmol/L) 1.54 (1.27–2.29) 1.89 (1.17–2.95) 2.11 (1.47–2.97) 1.94 (1.40–3.05) 2.64 (0.108) 0.14 (0.707) 0.23 (0.631)
Total cholesterol (mmol/L) 5.69±1.05 5.86±0.73 6.04±1.14 5.98±1.14 0.39 (0.535) 2.32 (0.133) 1.24 (0.269)
LDL-C (mmol/L) 3.26±0.79 3.67±0.97 3.82±0.97 3.76±1.14 0.11 (0.737) 1.48 (0.227) 5.04 (0.028)
HDL-C (mmol/L) 1.12±0.18 1.07±0.21 1.10±0.21 1.14±0.21 0.24 (0.629) 0.26 (0.612) 0.13 (0.716)
Serum hormones
Cortisol (ng/mL) 313.89±87.84 296.45±63.02 200.57±71.61 215.12±51.39 1.58 (0.212) 5.19 (0.026) 1.91 (0.171)
DHEA-S (µg/mL) 1.75 (1.32–3.12) 1.27 (0.79–1.78) 1.00 (0.56–1.52) 0.43 (0.30–0.70) 8.14 (0.006) 4.86 (0.031) 0.04 (0.834)
Prolactin (ng/mL) 5.96 (4.69–7.73) 11.48 (7.38–15.82) 5.90 (4.48–8.94) 10.90 (7.30–12.86) 5.40 (0.023) 2.92 (0.092) 4.06 (0.055)
CRP (mg/L) 1.70 (0.90–3.80) 1.20 (0.90–2.10) 2.00 (1.00–3.40) 1.50 (0.70–2.10) 0.62 (0.435) 1.87 (0.175) 1.78 (0.675)
DHEA-S, dehydroepiandrosterone-sulfate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PTSD, post-traumatic stress disorder;
Q1–Q3, interquartile range; SD, standard deviation.
aVariables represented by median (Q1–Q3) were log-transformed.
bStatistically significant (p<0.05) results are shown in bold.
Table 3 | Comparison of multiplex assay analytes between PTSD patients and controls at the first assessment.
Analyte Assay
sensitivity
PTSD (n=69) Controls (n=32) Statistical
valuea
d -valueb p-valuec
Median (Q1–Q3) Detectable (%) Median (Q1–Q3) Detectable (%)
sCD40L 0.02 ng/mL 4.72 (3.95–5.89) 69 (100) 4.51 (3.01–5.87) 32 (100) 1.02 0.027 0.313
sPECAM-1 0.8 ng/mL 229.76 (179.67–288.12) 69 (100) 191.52 (163.61–224.08) 32 (100) 1.15 0.025 0.253
sICAM-1 5.3 ng/mL 620.29 (484.78–854.38) 69 (100) 635.18 (468.07–917.76) 32 (100) 0.18 0.046 0.862
Leptin 0.05 ng/mL 17.97 (9.03–24.97) 69 (100) 15.52 (11.31–21.75) 32 (100) −0.42 0.042 0.672
MIP-1α 1.0 pg/mL 31.28 (5.82–134.07) 55 (79) 48.25 (12.41–203.18) 27 (84) −1.01 0.029 0.313
IL-8 0.5 pg/mL 39.50 (0.00–112.88) 45 (65) 184.58 (60.1–397.40) 29 (91) −4.37 0.006 <0.001*
IL-1β 4.2 pg/mL 0.00 (0.00–34.47) 35 (51) 5.95 (0.00–17.34) 18 (56) 0.21 0.048 0.826
IL-2 16.4 pg/mL 0.00 (0.00–0.00) 15 (22) 0.00 (0.00–0.00) 4 (13) Exact 0.033 0.412
TNF-α 3.2 pg/mL 0.00 (0.00–0.00) 14 (20) 0.00 (0.00–0.00) 4 (13) Exact 0.035 0.413
IFN-γ 1.6 pg/mL 0.00 (0.00–0.00) 13 (19) 0.00 (0.00–0.00) 2 (6) Exact 0.019 0.135
NGF 126.8 pg/mL 0.00 (0.00–0.00) 6 (9) 0.00 (0.00–0.00) 1 (3) Exact 0.037 0.427
IL-4 20.8 pg/mL 0.00 (0.00–0.00) 4 (6) 0.00 (0.00–0.00) 1 (3) Exact 0.038 0.491
IL-6 1.2 pg/mL 0.00 (0.00–0.00) 1 (1) 0.00 (0.00–0.00) 1 (3) Exact 0.040 0.535
IFN-γ, interferon-γ; IL, interleukin; MIP-1α, macrophage inflammatory protein-1α; NGF, nerve growth factor; PTSD, post-traumatic stress disorder; Q1–Q3, interquartile
range; sCD40L, soluble CD40 ligand; SD, standard deviation; sICAM-1, soluble intercellular adhesion molecule-1; sPECAM-1, soluble platelet endothelial cell adhesion
molecule-1; TNF-α, tumor necrosis factor-α.
at-value: independent sample t-tests calculated for log-transformed variables (except IL-1β, Z-value: Mann–Whitney’s test), “Exact”: Fisher’s exact test.
bFalse discovery rate threshold value (d) calculated with significance level (α) set to 0.05 for 26 comparisons.
cThe difference is considered significant at α=0.05 if p-value is less than the corresponding d value (labeled with *).
STAI-Trait testing showed fair to good reproducibility while
full scale LASC, BDI, and STAI-State were associated with poor
reproducibility.
Fair agreement between measurements was observed for IL-
2 and NGF. Measurements of IL-4 and IFN-γ showed moderate
and good agreement, respectively. Detection of TNF-α and IL-6
showed poor agreement between measurements.
CORRELATIONS BETWEEN BIOLOGICAL VARIABLES AND
PSYCHOMETRIC TEST SCORES
No correlation between psychometric test scores and biological
variables in the group of PTSD patients was found to be signifi-
cant after FDR correction for multiple correlations. However, we
decided to report initially significant correlations as a guideline
for future studies. Patients with detectable levels of IL-4 tended
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Table 4 | Comparison of multiplex assay analytes in PTSD patients (n=47) between two assessments.
Analyte Median (Q1–Q3) Detectable (%) Statistical valuea d -valueb p-valuec
Time 1 Time 2 Time 1 Time 2
sCD40L 4.76 (3.75–5.68) 4.26 (3.71–4.78) 47 (100) 47 (100) −3.99 0.008 <0.001*
sPECAM-1 204.84 (166.08–286.69) 162.17 (120.78–213.94) 47 (100) 47 (100) −5.82 0.002 <0.001*
sICAM-1 589.47 (470.83–787.31) 635.40 (468.53–1008.13) 47 (100) 47 (100) 1.32 0.021 0.194
Leptin 15.73 (8.41–26.67) 13.50 (0.66–23.18) 47 (100) 47 (100) 1.73 0.015 0.091
MIP-1α 30.28 (0.00–111.81) 32.33 (14.76–67.67) 35 (75) 43 (92) 1.20 0.023 0.236
IL-8 33.95 (0.00–135.12) 191.87 (55.22–405.51) 31 (66) 40 (85) 4.65 0.004 <0.001*
IL-1β 0.00 (0.00–34.47) 18.21 (0.00–31.51) 21 (44) 32 (68) 2.13 0.013 0.012*
IL-2 0.00 (0.00–0.00) 0.00 (0.00–100.53) 9 (19) 21 (45) Exact 0.010 0.004*
TNF-α 0.00 (0.00–0.00) 0.00 (0.00–10.63) 10 (21) 12 (26) Exact 0.044 0.791
IFN-γ 0.00 (0.00–0.00) 0.00 (0.00–0.00) 10 (21) 7 (15) Exact 0.031 0.375
NGF 0.00 (0.00–0.00) 0.00 (0.00–0.00) 5 (11) 1 (2) Exact 0.017 0.125
IL-4 0.00 (0.00–0.00) 0.00 (0.00–0.00) 4 (9) 4 (9) Exact 0.050 0.999
IL-6 0.00 (0.00–0.00) 0.00 (0.00–0.00) 1 (2) 9 (19) Exact 0.040 0.008*
SeeTable 3 for abbreviations.
at-value: dependent sample t-tests calculated for log-transformed variables (except IL-1β, Z-value: Wilcoxon signed-rank tests), “Exact”: McNemar’s exact test.
bFalse discovery rate threshold value (d) calculated with significance level (α) set to 0.05 for 26 comparisons.
cThe difference is considered significant at α= 0.05 if p-value is less than the corresponding d value (labeled with *).
to score higher on LASC re-experiencing cluster of symptoms
(ρ= 0.26, p= 0.032) at the first assessment. NGF levels above LOD
were associated with higher severity of all three clusters of symp-
toms (re-experiencing: ρ= 0.24, p= 0.046; avoidance: ρ= 0.27,
p= 0.024; arousal: ρ= 0.26, p= 0.028) at the first assessment
time point. At the second assessment, avoidance symptoms were
positively associated with sPECAM-1 concentration (ρ= 0.30,
p= 0.044). Chemokine levels at the first assessments were posi-
tively correlated with arousal symptoms at the second assessment
(MIP-1α, ρ= 0.29, p= 0.027; IL-8, ρ= 0.29, p= 0.027). Higher
PTSD symptom severity at the first assessment was associated
with lower cortisol levels at the second assessment (avoidance:
ρ=−0.31, p= 0.035; 17-item PTSD index: ρ= 0.28, p= 0.026).
DISCUSSION
We found a robust association of combat-related chronic PTSD
with higher serum levels of DHEA-S and lower levels of prolactin.
The observed differences between PTSD patients and healthy con-
trols persisted after 3 months. Repeated measurements of these
markers were associated with good to excellent reproducibil-
ity. Cortisol levels were stable neither in PTSD patients nor in
controls, and its determination was associated with poor repro-
ducibility. Out of all cytokines and other immune-related markers
measured, only IL-8 was significantly lower in PTSD patients in
comparison to healthy controls. However, its concentration was
not stable in PTSD patients as shown by a significant increase
after 3 months and repeated measurements showed poor repro-
ducibility. Although serum lipids did not differ between patients
and controls in individual time points, a significant elevation of
LDL-C was observed in PTSD patients.
The observed lack of difference in serum lipids is in line with
a previous study of Croatian combat veterans with PTSD (35).
In this study, patients were medicated and the authors argued
that the combination of drugs might have affected final serum
lipid levels although they did not control for medication in analy-
ses. In the present study, we tried to control for medications
that patients used and observed the opposite effect of atypi-
cal antipsychotics and hypolipidemics on total cholesterol levels,
which was not surprising. Evidence supports efficacy of antipsy-
chotics in treatment-resistant PTSD (63) and they are commonly
used in treatment of combat veterans in Croatia (64). However,
antipsychotics induce various metabolic alterations including dys-
lipidemia (65) so the use of hypolipidemics is justified. Previously
studied samples of combat veterans with PTSD that exhibited ele-
vated serum lipids did not include patients using antipsychotics
(13, 15, 66) or lipid-lowering drugs (10). When we excluded the
patients taking antipsychotics and hypolipidemics from analyses,
the results remained the same, i.e., no difference in serum lipids
at individual time points. However, we have observed a significant
elevation in LDL-C after 3 months in PTSD patients but not in
the control group. This tendency was observed for triglycerides
and total cholesterol as well and it was even statistically signifi-
cant when patients using antipsychotics and hypolipidemics were
excluded from analyses (data not shown). Even if these findings
are related to factors that were not controlled for, such as poor
diet or lack of exercise, this information clearly shows that PTSD
patients may be more prone to dyslipidemia, which is in line with
recent findings of higher prevalence of metabolic syndrome in
PTSD patients (17, 67).
Disrupted lipid metabolism may be associated with dysregu-
lation of the HPA axis (19) but this was not evident from find-
ings of basal morning cortisol levels in our study. We observed
no difference between PTSD patients and controls and cortisol
levels declined in both groups after 3 months. Low ICC (i.e.,
the poor reproducibility) indicated that cortisol determination
was associated with low correlation between measurements, high
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Table 5 | Intraclass correlation coefficient (ICC) and agreement
between measurements.
ICC (95% CI) or kappa
Serum lipids
Triglycerides 0.56 (0.40–0.69)
Total cholesterol 0.69 (0.57–0.77)
LDL-C 0.63 (0.48–0.74)
HDL-C 0.73 (0.61–0.81)
Serum hormones
Cortisol −0.17 (−0.37 to 0.03)
DHEA-S 0.50 (0.33–0.64)
Prolactin 0.79 (0.69–0.85)
CRP 0.41 (0.21–0.57)
Multiplex analytes
sCD40L 0.41 (0.14–0.63)
sPECAM-1 0.77 (0.62–0.86)
sICAM-1 0.59 (0.37–0.75)
Leptin 0.78 (0.63–0.87)
MIP-1α 0.85 (0.74–0.91)
IL-8 −0.08 (−0.36 to 0.21)
IL-1β 0.91 (0.85–0.95)
IL-2 0.271
TNF-α 0.171
IFN-γ 0.643
NGF 0.309
IL-4 0.453
IL-6 0.168
Psychometric tests
LASC 17-item PTSD index 0.45 (0.27–0.60)
LASC 43-item full scale index 0.39 (0.20–0.55)
BDI 0.06 (−0.15 to 0.26)
STAI-State 0.10 (−0.10 to 0.30)
STAI-Trait 0.45 (0.27 to 0.60)
CI, confidence interval; for others, seeTables 1–4.
between-subject, and low within-subject variance. This may be
related to high biological variability of morning serum cortisol lev-
els and/or measurement error associated with the method used to
determine cortisol concentrations. We used enzyme immunoassay,
which is comparable to radioimmunoassay (68), the most often
used assay in PTSD-related basal cortisol studies. Both immunoas-
says exhibit cross-reactivity and specificity issues, especially if
serum levels of cortisol are high (68) (in our study both PTSD
patients and controls had cortisol levels around upper limits of the
standard reference range). The use of gas chromatography–mass
spectrometry may result in more reliable results (69). In addition,
the observed decline in serum cortisol levels in both groups after
3 months may be due to seasonal variation (70), which must be
taken into account as another source of variability in study design
(duration of participant recruitment).
Although cortisol levels were not altered in PTSD patients,
DHEA-S, which is also partly secreted from the adrenal gland in
response to ACTH stimulation, was significantly higher in PTSD
patients and repeated measurements were associated with good
reproducibility. Circulatory DHEA-S levels were found to be ele-
vated in chronic combat-related PTSD (27) and chronic PTSD
with the history of childhood abuse (28, 43). Our study also partly
replicated the findings from another longitudinal study (29) where
PTSD patients tended to have higher DHEA-S levels across four
time points separated by 3 months. However, authors did not pro-
vide information about the time span of participant recruitment
and did not report significant changes over time. The significant
decline of DHEA-S in both groups after 3 months observed in our
study may be associated with seasonal variation as shown by Grade
et al. (71) in healthy women (with lowest levels during summer
and winter) even though a more recent study did not confirm sea-
sonal variation of DHEA-S in either sex (72). Nevertheless, our
results indicate that this source of variability should be considered
in study design and that it may have contributed to negative find-
ings of DHEA-S in PTSD (30, 40, 73). Robust results of elevated
DHEA-S provide additional evidence of dysregulated HPA axis
in chronic combat-related PTSD and highlight the importance of
DHEA-S not only as a disease marker but also as a possible recovery
marker (42) and, as shown recently, a susceptibility marker (74).
The finding of lower prolactin levels in PTSD patients may
also be associated with dysregulation of the HPA axis. Previous
studies showed enhanced prolactin suppression after a dexametha-
sone challenge in combat veterans with PTSD (38, 75) indicating
that PTSD patients may be more prone to glucocorticoid-related
modulation of factors involved in prolactin release. These factors
could include serotonin since PTSD patients showed decreased
prolactin response to serotonin-releasing agent (d-fenfluramine)
compared to healthy controls (76). Although basal levels of pro-
lactin were not altered in these studies, perhaps due to low sample
sizes and lack of power, Olff et al. (40) found lower prolactin lev-
els in chronic PTSD patients, which is consistent with our results.
However, no changes in basal prolactin levels were also reported
(39, 41) and one longitudinal study showed elevated prolactin lev-
els in Croatian combat veterans with PTSD (24). The difference
from the latter study may be because veterans were assessed ear-
lier in the course of disease. Besides, elevated prolactin may have
reflected residual effects of medication after a washout period (77).
Considering medication, we expected to find higher prolactin lev-
els in our sample of PTSD patients. Indeed, patients who were
using antipsychotics tended to have higher levels of prolactin at
the first assessment but this difference was not statistically signif-
icant. No significant association with other drugs was observed.
Despite the use of prolactin-elevating medication, PTSD patients
showed decreased prolactin levels that were stable after 3 months
and its determination was associated with excellent reproducibil-
ity. This finding marks the importance of prolactin as a putative
stable, although indirect, marker of enhanced HPA axis negative
feedback system (78).
Despite known immuno-modulatory properties of DHEA-S
(26) and prolactin (23), PTSD patients in our study did not show
alterations in circulating levels of CRP or in pro-inflammatory
cytokines (IL-1β, TNF-α, IL-6) in comparison to healthy controls.
Cytokines associated with cell-mediated (Th1: IFN-γ, IL-2) and
humoral (Th2: IL-4) immunity were not altered as well. Current
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findings in PTSD point to enhanced inflammation with disturbed
Th1/Th2 balance (20,79). There is also evidence of insufficient reg-
ulation of immune function as shown by reduction of regulatory
T cells (Treg) in refugees with chronic PTSD (80). By analyzing
Tregs in a random subset of PTSD patients from this study, we
have found that they exhibit a different phenotype of Tregs that
might be less suppressive (52). Although no difference in CRP
and cytokines was observed between patients and controls at the
first assessment, impaired immune regulation might be reflected
in the significant rise and/or more patients having detectable lev-
els of pro-inflammatory (IL-1β, IL-6) and Th1 (IL-2) cytokines
after 3 months during winter when viral exposure was higher.
Unfortunately, control subjects were not assessed at the second
assessment so we could not test the hypothesis of higher suscep-
tibility of PTSD patients to inflammatory responses. However,
IL-1β determination was associated with excellent reproducibility.
With previous evidence of elevated IL-1β in PTSD (81–83), fur-
ther prospective studies examining the dynamics of this marker
in PTSD are warranted. As for other pro-inflammatory cytokines
(IL-6, TNF-α), the multiplex assay that we used was not sensi-
tive enough to allow quantitative analyses. This was most evident
for IL-6 with only one detectable sample at the first assessment.
Low agreement between repeated detections of IL-6 and TNF-α
suggests high variability over time with many samples that were
negative at the first assessment being positive at the second and
vice versa.
As for chemokines, in contrast to one previous study (22), MIP-
1α was not elevated in PTSD patients but we found lower levels
of IL-8, another chemokine that has already been found to be
decreased in earthquake survivors with PTSD (84). This signifi-
cance was attenuated after controlling for confounding factors and
IL-8 levels were not stable, as seen by significant elevation after
3 months. Moreover, its measurements were associated with poor
reproducibility which may in some extent explain different find-
ings across studies (22, 45, 84). Interestingly, both chemokine levels
at the first assessments were positively correlated with arousal
symptoms after 3 months, which indicates possible predictive
value of these markers.
An association of PTSD with higher levels of soluble adhe-
sion molecules has been demonstrated in PTSD after myocar-
dial infarction (85) and accidents (86) but a negative finding of
sICAM-1 has also been reported (87). In the present study, nei-
ther concentrations of adhesion molecules (sICAM-1, sPECAM-1)
nor levels of costimulatory molecule sCD40L were significantly
altered in PTSD relative to healthy controls. These inflamma-
tory markers are associated with endothelial dysfunction and
platelet activation, playing a potential role as predictors of CVD
(88). Von Känel et al. (89) found lower plasma sCD40L levels
in patients with PTSD caused by myocardial infarction but only
after controlling for depression symptoms, which positively cor-
related with sCD40L levels. PTSD patients in our study showed
a significant decline in depression symptoms after 3 months,
which may explain the observed decline in serum sCD40L lev-
els. Since we have observed improvement of PTSD symptoms
as well, in parallel with sPECAM-1 decline, adhesion molecules
and sCD40L need further attention, possibly as therapy mark-
ers, especially because their determination was associated with
good to excellent reproducibility. Moreover, sPECAM-1 tended
to positively correlate with avoidance symptoms at the second
assessment.
Given their important role in stress-related psychopathology
(90, 91), it is surprising that leptin and NGF have not been
more extensively studied in PTSD. One of the two leptin studies
demonstrated elevated leptin in PTSD patients after myocardial
infarction (89) and another in earthquake survivors with subsyn-
dromal PTSD (92). We did not replicate these results and found no
difference between PTSD patients and controls without changes
in the PTSD group after 3 months. Leptin levels were affected by
hypolipidemics but the difference between patients and controls
remained non-significant even after patients using lipid-lowering
drugs were excluded from analyses.
To our knowledge, soluble NGF has not been measured in
PTSD. Unfortunately, the assay that we used was not sensitive
enough to allow quantitative analyses. However, a small number
of patients with detectable NGF at the first assessment tended to
have more pronounced PTSD symptoms. Arousal or anxiety states
are often accompanied by increases in NGF levels, which possibly
reflect a central neuroprotective homeostatic mechanism with the
potential to activate neuroendocrine and immune elements at the
periphery (91). New evidence suggests that NGF can also be mea-
sured in saliva in response to stress (93). With the evidence of
altered peripheral levels of other neurotrophins in PTSD (94, 95),
future studies of NGF using more sensitive assays are warranted.
Although PTSD symptoms may fluctuate over time (96), we
observed a significant decline in all three clusters of self-reported
PTSD symptoms after 3 months. Croatian war veterans perceive
extremely low levels of social acknowledgment (97) and the
patients possibly saw the research initiative as a kind of orga-
nized care intervention especially since all veterans were gathered
in the hospital in a single day for assessments. This itself might
have had a therapeutic effect and resulted in better adherence
to other forms of treatment, including medications. High moti-
vation was also evident in a low dropout rate after 3 months.
However, the observed changes in biological markers that were
associated with PTSD (i.e., DHEA-S, prolactin) were parallel in
both patients and controls. On the other hand, the possibility
remains that the changes observed in markers that were not mea-
sured in controls at the second assessment were associated with the
improvement of symptoms. As mentioned before, the observed
decline in sCD40L and sPECAM-1 needs further attention with
better assessment of PTSD symptoms and in relation to specific
therapeutic procedures.
STRENGTH AND LIMITATIONS
One of the limitations of the study is that we did not administer
structured interviews for assessment of the symptoms. The main
reason for using self-report scales was time constraint, since we
wanted to perform all assessments in a single day to minimize
sources of variability. PTSD patients comprised a very homoge-
neous group of severely traumatized combat veterans who started
their treatment shortly after the war in Croatia. Since then, they
have participated in various treatment programs and they have
been assessed with various instruments on multiple occasions
according to multimodal assessment principles (98), including
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Clinician-Administered PTSD Scale (CAPS) (99). Furthermore,
we excluded patients who did not satisfy criteria for PTSD accord-
ing to LASC diagnostic items. Besides, repeated assessments of
LASC 17-item PTSD index showed good reproducibility, which
adds to the reliability of diagnosis. Another caveat is that we did
not specifically control for possible comorbid depression although
BDI scores were relatively high on the day of the first assessment.
However, while some biological measures tended to correlate with
severity of PTSD symptoms, no correlation was found with BDI
scores at either assessment. Moreover, BDI scores at the second
assessment indicated mild depression at most. The use of med-
ication is another limitation, which could not be avoided due to
ethical reasons. We tried to control for drugs that patients used in
statistical analyses. The use of antipsychotics and hypolipidemics
had a significant effect on several variables but we decided not to
exclude those patients to preserve power. Analyses of multiplex
analytes could not be modeled entirely to include covariates so we
excluded patients using those drugs and the results for affected
analytes remained similar (sICAM-1, MIP-1α, and leptin). Finally,
the study did not have available body mass index (BMI) data. In
our previous study on another sample of PTSD patients from the
same area (meaning similar lifestyle and dietary habits), we found
no difference between PTSD patients and healthy controls regard-
ing BMI (100). Both groups were slightly overweight in line with
the study encompassing a larger sample of Croatian war veterans
with PTSD and without PTSD in comparison to a nation-wide
civilian sample (101). Considering all this, we presume that BMI
did not have large effect on the comparison of variables known to
be affected by BMI.
The main strength of the current study is that we measured
a wide array of biological variables in a relatively large group of
PTSD patients and repeated the measurements after a reasonable
period to assess how stable observed changes are over time. All
participants were assessed in a single day at each assessment time
point and blood was drawn in the morning during a limited period,
thus minimizing circadian and eliminating monthly and seasonal
variations in biological variables. The same group of profession-
als performed assessments at both time points using the same
methods. This allowed us to compare intra- and inter-individual
variability and provide reliability estimates as a guideline for future
studies. The assessment of the control group at both time points
enabled us to test if the changes over time in a number of variables
were specifically related to PTSD.
CONCLUSION
Although many biological alterations have been reported in PTSD,
no reliable and specific PTSD biomarker has been identified to
date (46). Differences in findings across studies may be explained
by variations in sample sizes, sample characteristics (e.g., type
of trauma, time elapsed since trauma, comorbidities), and large
inter-individual variability of biological variables. One of the
requirements that PTSD biomarkers should fulfill is reliability, i.e.,
repeated testing should produce similar results. The results of our
repeated assessments indicate that some biological changes may
persist over a longer period during the course of chronic PTSD in
treatment-resistant war veterans and have potential to be reliable
markers of disease (e.g., DHEA-S and prolactin). Other alterations
were not so constant, such as serum lipids and cytokines, but
the observed changes probably did reflect differences in reactivity
of neuroendocrine-immune networks. Regardless of which direc-
tion the change takes, disrupted homeostasis may eventually lead
to disease. Given the seasonal variations of some variables and
high intra-individual variability, cross-sectional studies should be
carefully designed with participant recruitment over a very lim-
ited time period. Additionally, this emphasizes the importance of
longitudinal studies in investigations of PTSD biomarkers.
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